Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

NCT06244771 is registered in ClinicalTrials.gov with Frontier Medicines Corporation as lead sponsor.

NCT NCT06244771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06244771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors
Lead sponsor
Frontier Medicines Corporation
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 12, 2024
Completion date
April 30, 2028
Enrollment
403 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors with kras g12c mutations, colorectal cancer, kras g12c, metastatic solid tumor, non small cell lung cancer, pancreatic cancer, solid tumor, adult, unresectable solid tumor